hMAO-B-IN-2 is an orally active, selective, blood-brain barrier permeable, and competitive reversible hMAO-B inhibitor with an IC50 of 4 nM; it exhibits low cytotoxicity toward SH-SY5Y cells and demonstrates good neuroprotective effects; it can be used in the study of Alzheimer's disease; it serves as a click chemistry reagent containing an alkyne group that undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules.